Invitae Co. (NYSE:NVTA) CAO Robert F. Werner bought 2,427 shares of the agency’s stock in a transaction that occurred on Tuesday, November 24th. The shares had been bought at a mean price of $48.92, for a complete value of $118,728.84. The sale was disclosed in a doc filed with the Securities & Alternate Fee, which is offered by way of this hyperlink.
Robert F. Werner additionally lately made the next commerce(s):
- On Thursday, September 10th, Robert F. Werner bought 246 shares of Invitae stock. The shares had been bought at a mean price of $33.87, for a complete value of $8,332.02.
Invitae stock traded up $3.21 throughout mid-day buying and selling on Friday, reaching $50.06. 1,966,734 shares of the corporate’s stock had been exchanged, in comparison with its common quantity of three,031,407. The enterprise’s fifty day easy shifting common is $46.49 and its 200 day easy shifting common is $33.33. The agency has a market capitalization of $8.28 billion, a PE ratio of -12.85 and a beta of two.15. Invitae Co. has a one 12 months low of $7.41 and a one 12 months excessive of $55.38. The corporate has a fast ratio of three.71, a present ratio of three.71 and a debt-to-equity ratio of 0.69.
Invitae (NYSE:NVTA) final issued its earnings outcomes on Thursday, November fifth. The medical analysis firm reported ($0.78) earnings per share (EPS) for the quarter, lacking the Thomson Reuters’ consensus estimate of ($0.60) by ($0.18). The agency had income of $68.73 million through the quarter, in comparison with the consensus estimate of $59.36 million. Invitae had a unfavorable web margin of 182.73% and a unfavorable return on fairness of 77.82%. The enterprise’s quarterly income was up 21.6% in comparison with the identical quarter final 12 months. Throughout the identical quarter within the earlier 12 months, the agency earned ($0.82) earnings per share. On common, sell-side analysts forecast that Invitae Co. will put up -2.53 earnings per share for the present 12 months.
A number of brokerages lately issued stories on NVTA. JPMorgan Chase & Co. reduce Invitae from an “obese” score to a “impartial” score and set a $45.00 goal price on the stock. in a analysis report on Wednesday, October 14th. SVB Leerink lifted their goal price on Invitae from $34.00 to $44.00 and gave the corporate an “outperform” score in a analysis report on Tuesday, November third. LADENBURG THALM/SH SH reduce Invitae from a “purchase” score to a “impartial” score in a analysis report on Friday, November sixth. They famous that the transfer was a valuation name. Zacks Funding Analysis raised Invitae from a “promote” score to a “maintain” score in a analysis report on Wednesday, November 18th. Lastly, Morgan Stanley lifted their goal price on Invitae from $38.00 to $41.00 and gave the corporate an “equal weight” score in a analysis report on Friday, November sixth. 5 funding analysts have rated the stock with a maintain score and 4 have assigned a purchase score to the stock. The stock presently has a consensus score of “Maintain” and a mean goal price of $40.16.
Institutional traders and hedge funds have lately modified their holdings of the enterprise. State Board of Administration of Florida Retirement System grew its place in Invitae by 1.9% through the third quarter. State Board of Administration of Florida Retirement System now owns 48,479 shares of the medical analysis firm’s stock worth $2,102,00Zero after shopping for a further 910 shares within the final quarter. Nuveen Asset Administration LLC raised its place in shares of Invitae by 16.4% within the second quarter. Nuveen Asset Administration LLC now owns 724,843 shares of the medical analysis firm’s stock worth $21,956,00Zero after buying a further 102,309 shares through the interval. Rafferty Asset Administration LLC raised its place in shares of Invitae by 120.8% within the second quarter. Rafferty Asset Administration LLC now owns 59,072 shares of the medical analysis firm’s stock worth $1,789,00Zero after buying a further 32,314 shares through the interval. Canada Pension Plan Funding Board acquired a brand new place in shares of Invitae within the second quarter worth about $32,240,000. Lastly, Glenmede Belief Co. NA raised its place in shares of Invitae by 72.7% within the second quarter. Glenmede Belief Co. NA now owns 13,926 shares of the medical analysis firm’s stock worth $421,00Zero after buying a further 5,860 shares through the interval. Hedge funds and different institutional traders personal 98.58% of the corporate’s stock.
Invitae Firm Profile
Invitae Company, a medical genetics firm, processes DNA-containing samples, analyzes data associated to patient-specific genetic variation, and generates take a look at stories for clinicians and their sufferers in america, Canada, and internationally. It gives genetic exams in varied scientific areas, together with hereditary most cancers, cardiology, neurology, pediatrics, metabolic circumstances, and uncommon ailments; prenatal and perinatal genetic exams; and non-invasive prenatal screening merchandise.
Featured Story: What’s the Fibonacci sequence?
This immediate information alert was generated by narrative science expertise and monetary information from MarketBeat with a view to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to [email protected]